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Abstract Chromium(III)isconsideredasanessentialelementplayingaroleincarbohydrateand
lipid metabolism, and various chemical forms of this element are widely used in dietary
supplements. A new trinuclear chromium(III) glycinate complex [Cr3O(NH2CH2CO2)6
(H2O)3]
+NO3
− (CrGly), an analogue of Cr3 (trinuclear Cr(III) propionate complex) has been
synthesized as a potential source of supplementary Cr. In this study, we evaluated the acute
toxicityclassofCrGlyinWistarratsapplyingtheOECD423procedure.MaleandfemaleWistar
rats (n=12, 6 ♀ and 6 ♂) were given by gavage either a single dose of CrGly 2,000 mg/kg
body mass (equals to 300 mg Cr(III)/kg body mass; in aqueous solution) or equivalent
volumes of distilled water and fed ad libitum commercial Labofeed B diet, and observed
carefully for 14 days, then sacrificed to collect blood and internal organs for biochemical and
histologic examination. No death cases were detected. No abnormalities in animal behavior,
body mass gains, gross organ histology, or blood morphology and biochemistry were
observed. The results demonstrate that LD50 of CrGly is greater than 2,000 mg/kg when
administrated orally to rat; thus, this compound appears to belong to the fifth category in the
GHS system or the fourth class (“unclassified”) in the EU classification system.
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Introduction
For 50 years, trivalent chromium (Cr) has been considered as an essential element playing
an important role in carbohydrate and lipid metabolism and providing significant beneficial
effects in the insulin system [1–4]. These effects appear to be related to an increase in
insulin sensitivity, with the proposed mechanisms reviewed in detail by Vincent and
Bennett [5]. However, the failure to identify the responsible biomolecules that bind Cr and
their mode of action made researchers to readdress the essentiality of this element [6]. In
short, the main controversy exists as to whether dietary supplementation with Cr should be
routinely recommended in subjects without documented deficiencies. The majority of
studies showed that supplementing the diet with nutritionally relevant quantities of Cr does
not give any beneficial effects, while effects from Cr may arise at pharmacological doses [6,
7]. Recent data fail to demonstrate a significant improvement in carbohydrate metabolism
in individuals with metabolic syndrome, impaired glucose tolerance, or consistently in
individuals with type 2 diabetes after Cr supplementation. Wang et al. [8] suggested that
only a subgroup of type 2 diabetic subjects respond positively to Cr supplementation and
subject’s phenotype appears to be very important when assessing the clinical response to
Cr. Wang and Celafu [9] recently postulated that patient selection may be an important
factor in determining clinical response to Cr (decreased glucose and improved insulin
sensitivity), as it may be more likely in insulin-resistant individuals with type 2 diabetes
who have more elevated fasting glucose and hemoglobin A(1c) levels.
Despite these controversies, over last decades Cr nutritional supplements become very
popular for weight loss, muscle development, and diabetes. As Cr supplements various
chemical forms of Cr(III), including Cr picolinate (CrPic), Cr histidinate (CrHis), Cr
nicotinate (CrNic; also known as Cr niacinate (CrN)), and a Cr complex of D-phenylalanine
(Cr(D-phe)3) have been used, patented, manufactured, and/or marketed worldwide.
The most popular chemical forms of Cr(III) used in dietary supplements are Cr(III) tris-
picolinate (CrPic) and Cr(III) nicotinate (CrNic). Over the last decades, sales of CrPic, as a
nutritional supplement for weight loss and increasing muscle mass, were increasing, and the
supplement was drawing interest for its potential use in alleviatingsymptoms of type 2 diabetes.
The beneficial action of CrPic on glucose and lipid metabolism and its helpful role in the
treatment of diabetes has been documented, but the mechanisms of action are not well
understood. On the other hand, CrPic has some drawbacks as a nutritional supplement. It has
verylimitedsolubilityinwater(0.6mM,atnearneutralpH)andstability(decreasesinlowerpH
until the complex hydrolyzes to release picolinic acid) [7, 10], which is responsible for its low
gastrointestinal absorption rate as 1% [6]. The safety of Cr(III) compounds used for dietary
supplements has been a matter of considerable debate over last decades. The discussion about
the toxic effects produced by CrPic have been reviewed recently [11] and will not be repeated
in this article. Because there is widespread human exposure to CrPic in dietary supplements,
recently Stout et al. [12] conducted toxicity and carcinogenicity studies of this compound (in
the monohydrate form) in male and female F344/N rats and B6C3F1 mice exposed in feed to
concentrations of 0, 2,000, 10,000, or 50,000 ppm for 2 years. Exposure to CrPic did not
induce biologically significant changes in survival, body mass, feed consumption, or non-
neoplastic lesions in rats or mice. In male rats, however, a statistically significant increase in
the incidence of preputial gland adenoma at 10,000 ppm was considered an equivocal finding.
CrPic was not carcinogenic to female rats or to male or female mice.
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supplements and therapeutics, of particular interest is the Cr(III) propionate cation
(CrProp), [Cr3O(O2CCH2CH3)6(H2O)3]
+, known as Cr3 [2, 13–18]. This compound
belongs to the trinuclear oxo-centered metal carboxylate assemblies of the general formula
[Me3O(O2CR)6L3]
+ (Me = trivalent 3d metal, R = aliphatic or aromatic group, L =
monodentate ligand). CrProp was found to mimic the ability of low-molecular-weight
chromium-binding substance or chromodulin to stimulate tyrosine kinase activity of the
insulin receptor. Clodfelder et al. [18] reported that [Cr3O(O2CCH2CH3)6(H2O)3]
+ is
absorbed with very high efficiency of 40–60%, while popular Cr supplements such as:
CrCl3, Cr(III) nicotinate, or CrPic are absorbed at only 0.5–1.3% of the gavaged dose. The
difference in the degree of absorption is readily explained by the stability and solubility of
the cation in the physiological milieu. The biological activity and safety of CrProp has been
studied on various experimental models. This compound given at a wide range of dosages
(up to 2,000 mg/kg body mass) to experimental animals was confirmed to be safe [19–24]
and does not exert genotoxic effects [25, 26].
Having assumed that the trinuclear oxo-centered Cr carboxylate structure is the key
element that determines high bioavailability and biological activity of a Cr(III) compound,
we synthesized a novel Cr(III) complex with glycine (CrGly), an analogue of CrProp. Its
fundamental physicochemical properties were determined with the use of thermoanalytical
and spectroscopic methods and compared to that of well-known trinuclear chromium(III)
complex with propionic acid. The new complex, similarly as previously studied CrProp, in
contrast to CrPic and CrNic, is also well soluble in water and thermally stable until
temperature of at least 220°C [27, 28].
The CrGly biological activity (together with other Cr(III) compounds, like
chromium chloride, histidinate, lactate, acetate, and propionate) was already tested in
vitro, using three experimental models: isolated rat liver membranes, cultured mouse
C2C12 myoblasts, and 3T3-L1 preadipocytes [29]. It was found that the examined Cr
(III) compounds, in contrast to the results of o t h e rl a be x p e r i m e n t si nv i t r o( w h i c hm a yb e
related to the specific experimental conditions applied in this experiment), did not elevate
the binding of insulin to the liver membranes. Moreover, chromium histidinate, lactate,
acetate, and propionate complexes diminished the specific binding of insulin. Simulta-
neously, chromium chloride, which did not significantly elevate insulin binding,
increased the number of membrane accessible particles of the insulin receptors. However,
it was accompanied by slightly diminished affinity of the receptor to the hormone.
Chromium acetate and propionate significantly diminished the binding capacity of the
low-affinity insulin receptor class. Investigations with the myoblast cell line C2C12 and
preadipocyte cell line 3T3-L1 did not allow differentiation of the influence of the
examined complexes on insulin binding. Immunodetection of phosphorylated forms of
IRS-1 showed that the chromium compounds modulated the transduction of the insulin
signal. Chromium glycinate, acetate, and propionate decreased the amount of IRS-1
phosphorylated at serine. Since it is generally thought that phosphorylation of serine in
IRS-1 may moderate insulin action, the above-mentioned chromium complexes may, in
this way, enhance insulin effects inside target cells. Phosphorylation of tyrosine in IRS-1,
which acts as a stimulatory signal for further steps of insulin action, was elevated after the
incubation of 3T3-L1 cells with insulin. Cr(III) did not additionally intensify this process.
However, in the absence of insulin, chromium glycinate and acetate slightly elevated the
level of IRS-1 phosphorylated at tyrosine. This fact may be important in vivo at low
levels of insulin in blood. The results indicate that the action of chromium(III) complexes,
including CrGly, involves a direct effect on the number of receptors accessible to insulin,
1566 Staniek et al.their affinity to the hormone, and the modulation of the signal multiplying proteins by
their phosphorylation.
In the present study, we focused on the determination of the acute toxicity class of
CrGly (as an analogue of CrProp), when administered orally in a single dose to
Wistar rats. The study was performed in compliance with the Organization for




Chromium(III) complex with glycine (CrGly) in the form of nitrate salt (chemical
formula [Cr3O(NH2CH2CO2)6(H2O)3]
+NO3￿H2O, the theoretical content of Cr 25.7%),
as an analogue of chromium(III) propionate (CrProp; chemical formula [Cr3O
(O2CCH2CH3)6(H2O)3]
+NO3) was synthesized in our laboratory according to the method
described previously [28]. The product was recrystallized from water and then desiccated
under vacuum in temperature of 100°C. The product has a form of purple crystals, well
soluble in water. To ensure that molecular structure of synthesized complex corresponds
with the structure of the well-known chromium(III) propionate complex (Cr3) propionic
acid, some physicochemical properties of the new compounds were determined, including
thermal stability was determined by using DTA and TGA methods (module DTA-50,
Shimadzu). UV–VIS absorption spectra were obtained using Genesys 2 spectrophotom-
eter. IR spectra were recorded in KBr using Specord M-80 spectrophotometer [27, 28].
The analytically determined content of elemental Cr in the compound (17.3%) was
determined by the AAS method (spectrometer AAS-3 with BC correction, Zeiss,
Germany).
Acute Oral Toxicity Study in Male and Female Rats
For determination of the Acute Toxicity Class of CrGly, The OECD 423 Guideline For
Testing of Chemicals Acute Oral Toxicity—Acute Toxic Class Method [30] procedures
were applied as an alternative to the oral LD50 test [31]. Since the previous acute toxicity
study demonstrated that LD50 of CrProp is greater than 2,000 mg/kg when administrated
orally to rat, it was hypothesized that its analogue with glycine (CrGly) might also have a
low toxicity potential and mortality is unlikely, thus the test procedure applied with a
starting dose of 2,000 mg/kg body mass (per three animals of each sex). According to the
19th paragraph of the OECD-GL 423 procedure (OECD-GL 423, adopted in 17 December
2001) [30], when available information suggests that mortality is unlikely at the highest
starting dose level (2,000 mg/kg body weight), then a limit test should be conducted. The
limit test is primarily used in situations where the experimenter has information indicating
that the test material is likely to be non-toxic, i.e., having toxicity only above regulatory
limit doses.
Male and female Wistar rats (n=12, 6 ♂ and 6 ♀; age 12–14 weeks old), obtained from
Department of Toxicology Medical University of Poznan, Poland, were housed in the
University-approved animal facility in rooms maintained at 22±2°C, with 55–60% humidity
and 12-h photoperiod. After a 5-day adaptation to laboratory conditions, rats were divided
into four equal groups (controls—K♀,K ♂ and treated—T♀ and T♂,t h r e ea n i m a l si ne a c h
Trinuclear Chromium(III) Glycinate Complex in Rat 1567group, equal body mass) and given by gavage either a single dosage of 2,000 mg CrGly (in
aqueous solution)/kg body mass (treated groups, T♀ and T♂), or equal volumes of distilled
water (control groups, K♀ and K♂), using a suitably graduated syringe and a stainless steel
intubation cannula. The single dosage of CrGly equals approximately 420 mg Cr/kg body
mass/rat. Rats had free access to distilled water and commercial Labofeed B diet composed of
cereal grains (wheat, rye, soybeans, flax seeds), brewery yeast, potato protein, milk and whey
powder, mineral, and vitamin mix. The chemical composition of this diet (calculated per dry
mass) was as follows: protein (19.4%), fat (3.3%), dietary fiber (6.9%), crude ass (6.5%),
carbohydrates (63.9%), and metabolic energy (12.5 MJ/kg). The dietary Cr content was
determined by the AAS method (1.5 mg/kg diet)
Animals were observed individually after dosing at least once during the first 30 min,
periodically during the first 24 h, with special attention given during the first 4 h, and daily
thereafter, for a total of 14 days. All observations were systematically recorded with
individual records being maintained for each animal. Individual body masses of animals
were determined shortly before the test substance was administered and weekly thereafter.
All the animals were sacrificed at the end of the observation period and subjected to a
necropsy. All the procedures applied on animals were approved by the Local Bioethical
Commission in Poznan (No. 48/2005).
Data Collection
At the end of the test (14-day of experiment), animals, after 16-h starvation, were weighed
and euthanized by intraperitoneal injection of thiopental (40 mg/kg body mass) and
dissected to collect blood for morphological and biochemical studies and harvest internal
organs (liver, kidney, spleen, heart) for microscopic examination.
Laboratory Analyses
Blood hemoglobin (Hb) level was determined by the Drabkin’s cyanohemoglobin method.
Red blood count and related morphology indices were obtained by analytical hematology
system CELLDYN-1700 [32].
Blood serum indices were determined by the following methods: glucose concentration
by the UV photometric method [33] and total, LDL, HDL, and triacylglycerol
concentrations by the colorimetric methods [34–36] using Olympus AU 560 equipment.
Activity of ALT, AST, and AP enzymes was measured by the kinetic methods [37],
while urea concentration was measured by the kinetic method using urease and glutamine
dehydrogenase [38]. Total protein concentration was measured by the colorimetric method
using Cu
2+ ions [39], and creatinine concentration was measured by the Jaffe’s kinetic
method with picric acid [38]. The serum Fe concentration was determined by the
colorimetric method with 2,4,6-tri(2-pyridylo)-5-triazine [40]. The serum Na and K
concentrations were measured by the photometric method using CORMING-614 analyzer
[41].
Histology
A 3- to 5-mm section of the representative tissue (liver and kidney) was collected at the
time of sacrifice and preserved in 10% buffered formalin. Sections were processed by
standard histologic methods and embedded in paraffin. Slices were prepared and stained
with hematoxylin and eosin [42].
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All the analytical data are presented as means± SD, and observations for each rat were
recorded and presented in tables, while histologic images of liver and kidney tissue were
shown in figures.
Results and Discussion
As has been reported previously [11], the analysis of the toxicity is often a first step in the
study of biological properties of the compounds. The oral acute toxic class method (ATC
method) was developed as an alternative to replace the oral LD50 test. The ATC method is a
sequential testing procedure using only three animals of one sex per step at any of the
defined dose levels. Depending on the mortality rate of three, but never more than six,
animals are used per dose level. This approach results in the reduction of numbers of
animals used in comparison to the LD50 test by 40–70%. For the above reasons described
previously [11], this method was applied to test the acute toxicity class for CrGly.
Male and female Wistar rats, after administration of CrGly (2,000 mg/kg body mass) and
neutral carrier (distilled water) by gavage, were observed carefully during the 14-day
experimental period. None of the treated animals died during this period. Also no
pathological changes were noticed in skin, fur, and eyes, as well as in their behavior in
comparison with the control groups.
After 14 days of observations, all the rats were sacrificed and dissected to collect blood
from heart and remove internal organs for gross and histopathologic observations. No
pathological changes were observed in liver, kidney, heart, spleen, ovaries and testes, and
intestines, both in the treated male and female rats. Microscopic pictures (zoom ×100) of
liver and kidney tissue of the treated male and female rats are shown in Figs. 1 and 2. Oral
exposure to a single dosage of CrGly (2,000 mg/kg body mass) did not cause any
observable pathological changes in liver and kidney tissue.
Table 1 shows the overall somatic indices, such as body and internal organ masses, in
the treated and control rats. As can be seen, none of the studied parameters obtained for the
treated with CrGly male and female rats were significantly different from those of the
control group.
B) A)
Fig. 1 Histopathological images of liver (zoom ×100): a control group and b tested group exposure to
CrGly at dose 2,000 mg·kg
−1 body mass
Trinuclear Chromium(III) Glycinate Complex in Rat 1569Table 2 presents serum biochemical indices, including glucose, total cholesterol, HDL
cholesterol, LDL cholesterol, triacylglycerols, urea, creatinine, total protein concentrations,
serum Na, K, and Fe concentrations, as well as the activities of the enzymes (ALT, AST,
and AP), in the treated and control male and female rats. None of the above parameters
were changed in male and female rats treated with CrGly, in comparison with the control
groups.
B) A)
Fig. 2 Histopathological images of kidney (zoom ×100): a control group and b tested group exposure to
CrGly at dose 2,000 mg·kg
−1 body mass












Initial body mass (g) 306.2±8.2 306.2±4.3 NS 174.2±12.3 174.2±5.9 NS
Food intake (g) 341±21 309±37 NS 280±43 291±16 NS
Body mass gain (g) 24.250±8.057 17.500±10.786 NS 10.250±2.500 8.250±2.872 NS
Feeding efficiency
ratio (g/100 g diet)
7.031±2.040 5.405±2.942 NS 3.649±0.604 2.822±0.899 NS
Final body mass (g) 330±15 324±8 NS 184±12 182±8 NS
Liver mass (g) 9.527±0.158 9.327±0.328 NS 4.962±0.217 5.064±0.365 NS
Relative liver mass
(% b.m.)
2.886±0.096 2.881±0.048 NS 2.694±0.124 2.772±0.099 NS
Kidneys mass (g) 2.247±0.097 2.224±0.107 NS 1.368±0.108 1.305±0.032 NS
Relative kidneys
mass (% b.m.)
0.681±0.042 0.687±0.024 NS 0.741±0.033 0.716±0.032 NS
Spleen mass (g) 0.706±0.048 0.676±0.062 NS 0.420±0.056 0.421±0.036 NS
Relative spleen mass
(% b.m.)
0.214±0.023 0.209±0.019 NS 0.227±0.016 0.231±0.027 NS
Heart mass (g) 0.945±0.069 0.940±0.036 NS 0.587±0.068 0.580±0.038 NS
Relative heart mass
(% b.m.)
0.286±0.012 0.290±0.008 NS 0.317±0.017 0.318±0.008 NS
NS differences statistically non-significant
1570 Staniek et al.Tables 3 and 4 show blood morphological and hematological indices, including WBC,
RCB, LYMPH, PTL, MPV, PDW, hemoglobin, hematocrit, MCV, MCH, MCHC, and
RDW values in the treated and control male and female rats. Most of these indices were not
markedly different in animals treated with CrGly, except lower WBC (by 35%), LYMPH




























65.2±10.0 58.8±4.3 NS 60.0±5.7 60.5±6.6 NS
TAG concentration (mg·dl
−1) 25.5±2.6 29.2±8.3 NS 26.0±2.4 34.0±6.5 NS
ALT (U·dm
−3) 34.8±6.6 31.8±3.2 NS 29.0±4.2 28.5±3.3 NS
AST (U·dm
−3) 94.5±5.3 89.2±13.7 NS 102.2±21.6 119.2±46.6 NS
ALP (U·dm








0.55±0.06 0.52±0.05 NS 0.48±0.05 0.50±0.00 NS
Urea concentration (mg·dl
−1) 38.5±8.7 35.8±2.6 NS 34.8±5.2 34.8±3.5 NS
Na (mmol·dm
−3) 139.2±2.1 140.0±1.4 NS 137.5±5.8 138.5±0.6 NS
K (mmol·dm
−3) 4.2±0.1 4.1±0.1 NS 3.9±0.1 4.0±0.4 NS
Fe (μmol·dm
−3) 19.8±1.5 14.8±3.5 NS 67.0±7.9 55.6±8.0 NS
NS differences statistically non-significant
Table 3 Blood morphological indices of rats following exposure to 2,000 mg CrGly per kilogram body
mass (mean±SD)












a±0.42 p<0.05 1.48±1.02 1.40±0.38 NS
RBC (10
12·dm





a±0.4 p<0.05 1.9±1.3 1.3±0.3 NS
PLT (10
9·dm
−3) 1,182±104 1,072±49 NS 994±264 1103±51 NS
MPV (fl) 6.85±0.10 6.98±0.05 NS 6.92±0.28 6.88±0.15 NS
PDW (fl) 8.08±0.15 8.08±0.15 NS 8.08±0.35 8.18±0.26 NS
Different letters indicate a statistically significant difference at p<0.05
NS differences statistically non-significant, RBC red blood count
Trinuclear Chromium(III) Glycinate Complex in Rat 1571(by 38%), and MCHC (by 2%) values only in the case of male rats in comparison with the
appropriate control rats. However, these changes were still contained within the
physiological ranges established for healthy rats.
Chromium(VI) compounds generally are considered as more toxic than chromium
(III) compounds. For example, the LD50 for K2Cr2O7 (oral exposure) established in male
and female rats (Fisher-344) were, 26 and 17 mg/ kg body mass, respectively, for CaCrO4
in male and female rats (Sprague-Dawley), 249 and 107 mg/kg body mass, respectively
[43].
The acute toxicity of a Cr(III) compound depends on its nature and solubility in water.
Inorganic salts are more toxic than the organic ones. For example, LD50 for chromium
nitrate (Cr(NO3)3￿9H2O) in male and female rats is 200 and 183 mg kg
−1 body mass,
respectively, while for chromium(III) acetate (Cr(CH3COO)3￿H2O), LD50 was evaluated as
low (LD50=2,365 mg kg
−1 body mass) [43]. The lower toxicity of chromium(III) acetate
compared with chromium(III) nitrate may be related to its solubility, as chromium(III)
acetate is less soluble in water than is chromium(III) nitrate.
Niacin-bound Cr(III) complex was found to be non-toxic for Sprague-Dawley male
and female rats [44, 45], polynuclear Cr(III) complexes with natural ligands, including
glycine, cysteine, glutathione, glutaminic, nicotinic, and asparaginic acids, such as:
[Cr3(Glu)3Cys(OH)2(H2O)6], [Cr4Nic(GSH)2(OH)6(H2O)6], [CrNicCys(H2O)2],
[Cr2(Asp)2(GSH)(OH)3H2O]￿4H2O, [Cr2(Nic)2(OH)4]￿4H2O, [Cr(Nic)2(OH)]￿3H2O,
mer-[Cr(Gly)3H2O]￿H2O, and fac-[Cr(Gly)3H2O]￿H2O, were found to be “non-toxic”
(LD50>2,000 mg/kg body mass) for mice [46–48].
In our previous work, it was demonstrated that LD50 of CrProp is greater than
2,000 mg kg
−1 body mass, when administrated orally to rat; thus, this complex appears to
belong to the fifth category in the GHS system or the fourth class (“unclassified”) in the EU
classification system [11].
The results of this study assessing the acute oral toxicity of CrGly using both male and
female Wistar rats, due to lack of lethal effects and no significant changes in gross and
microscopic pictures of internal organs, as well as no sign of pathological changes blood
biochemical and morphological indices, suggest that the tested compound should be
classified (similarly to CrProp) to the fifth category in the United Nations Globally
Harmonized System [49] or the fourth class (“unclassified,” practically non-toxic) in the
European Union classification system [50], which means that CrGly has low toxicity
potential and relatively high safety margins for rat.
Table 4 Blood hematological indices of rats following exposure to 2,000 mg CrGly per kilogram body mass
(mean±SD)









−3) 14.6±0.5 13.8±0.6 NS 14.4±0.2 14.5±0.6 NS
HCT (%) 42.7±2.0 41.2±2.0 NS 42.3 ±1.0 43.1±1.7 NS
MCV (fl) 55.9±2.6 55.6±1.1 NS 56.8±1.4 55.8±1.2 NS




a±0.4 p<0.05 34.0±0.3 33.6±0.3 NS
RDW (%) 12.9±0.9 13.1±0.7 NS 12.7±0.4 12.8±0.8 NS
NS differences statistically non-significant
1572 Staniek et al.Inconclusion, the acute toxicity ofmanyCr(III) compounds had beendetermined,and most
of them should be considered acutely non-toxic, unless the ligands areknown to be toxic or the
compounds are complexes of imines or related ligands that greatly shift the redox potential of
Cr(III), such as Cr(bpy)3 or Cr(phen)3 that are known toxins and mutagens [51, 52].
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